Hepatitis B Virus remains a significant cause of morbidity and mortality worldwide. While numerous antiviral treatments are approved for use in the United States, determination of effective treatment strategies for long-term HBV suppression is challenging.
Viracor-IBT offers a comprehensive suite of molecular assays to assess:
- HBV viral load
- Antiviral resistance mutations
- Precore/core mutations
Comprehensive testing guides complex therapeutic decisions for chronic HBV patients by minimizing treatment failure and improving clinical outcomes. Viracor-IBT offers the superior line probe assay (LiPA) method for the assessment of antiviral resistance mutations, genotype, and precore/core mutations. LiPA detects mixed infections much earlier than sequencing assays which enables clinicians to modify treatment protocols in a more effective timeframe.
Viracor-IBT offers quantitative Hepatitis C Virus RNA viral load and genotype testing. Extensive genetic heterogeneity between the six major genotypes, and a propensity to mutate, makes assay design challenging. Viracor-IBT's assay design includes multiple targets to minimize the possibility of false negative results or underquantification due to sequence anomalies within an assay target.
The Viracor-IBT quantitative HCV RNA assay provides an extremely wide assay range of 24 to 1.3 x 108 IU/mL, detects all six genotypes, and has been calibrated to the World Health Organization HCV standard to provide accurate and consistent assessment of viral load across the entire assay range. Results below 50 IU/mL are reported as "Detected <24 IU/mL."
|Pathogen Load Monitoring||Hepatitis B Virus (HBV) Quantitative Real-time PCR|
|Hepatitis C Virus (HCV) Quantitative Real-time RT-PCR|
|Antiviral Resistance Assessment||Hepatitis B Virus (HBV) Antiviral Resistance LiPA|
|Pathogen Characterization||Hepatitis B Virus (HBV) Genotyping LiPA|
|Hepatitis B Virus (HBV) Precore Mutations LiPA|
|Hepatitis C Virus (HCV) Genotyping LiPA|